Does MTHFR A1298C rs1801131 AC modestly reduce methylation capacity and require homocysteine testing to assess cardiovascular risk?

The MTHFR A1298C (rs1801131) AC polymorphism is a common genetic variant located in the regulatory domain of the methylenetetrahydrofolate reductase enzyme. While frequently evaluated in cardiovascular risk assessments, its standalone biological impact is minimal.

Mechanistic and methylation impacts

• Enzymatic activity: The heterozygous AC genotype causes a mild 15% to 20% reduction in MTHFR enzyme activity, leaving individuals with 80% to 85% of normal wild-type function.
• Methylation capacity: This modest reduction is biochemically insufficient to clinically compromise methylation pathways or elevate plasma homocysteine levels under standard nutritional conditions.
• Compound heterozygosity: Clinically significant metabolic impacts generally only occur when the A1298C variant is co-inherited with the C677T mutation. This compound state reduces overall MTHFR activity to 50% to 60% of normal, which can elevate homocysteine.

Cardiovascular risk and clinical implications

• Genotype vs. biomarker: Because the isolated AC genotype does not elevate homocysteine, the genetic variant itself does not confer cardiovascular risk. Direct measurement of plasma homocysteine is required to determine whether an actual functional metabolic risk exists.
• Therapeutic limitations: Although elevated homocysteine is epidemiologically associated with cardiovascular disease, clinical trials show that lowering homocysteine levels via B-vitamin and folic acid supplementation does not reduce major cardiovascular events. Consequently, major medical organizations advise against routine MTHFR screening for primary cardiovascular prevention.

Bottom line

• The MTHFR A1298C AC genotype is functionally benign, causing only a mild 15% to 20% reduction in enzyme activity that does not independently elevate homocysteine or increase cardiovascular risk. While plasma homocysteine measurement is required to identify actual metabolic risk, clinical evidence shows that therapeutically lowering homocysteine does not translate to decreased cardiovascular events.